惰性淋巴瘤秋治疗进展.pptVIP

* There are 2 published studies looking at the role of Rituxan maintenance after R-monotherapy induction. These were performed by John Hainsworth and Michele Ghielmini. Hainsworth’s trial was in front-line indolent NHL patients. These patients included a group with SLL. Ghielmini’s trial included front-line and relapsed follicular NHL patients. After induction, there was a significant difference between the RR of the 57 chemotherapy-naive patients (RR 67% with 9% CR) and the 128 previously treated patients (RR 46% with 8% CR) (OR=2.34; P =.0097) The data above represents the best response d